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ABSTRACT
Aim To pilot enhanced safety surveillance of seasonal 
influenza vaccine meeting the European Medicines Agency 
(EMA) requirement to rapidly detect a significant increase 
in the frequency or severity of adverse events of interest 
(AEIs), which may indicate risk from the new season’s 
vaccine.
Study design A prospective passive enhanced safety 
surveillance combining data collection from adverse 
drug reaction (ADR) cards with automated collection of 
pseudonymised routinely collected electronic health record 
(EHR) data. This study builds on a feasibility study carried 
out at the start of the 2015/2016 influenza season. We will 
report influenza vaccine exposure and any AEIs reported 
via ADR card or recorded directly into the EHR, from the 
commencement of influenza vaccination and ends as 
specified by EMA (30 November 2016).
Setting Ten volunteer English general practices, primarily 
using the GSK influenza vaccines. They had selected this 
vaccine in advance of the study.
Participants People who receive a seasonal influenza 
vaccine, in each age group defined in EMA interim 
guidance: 6 months to 5 years, 6–12 years, 13–17 years, 
18–65 years and >65 years.
Outcome measures The primary outcome measure is 
the rate of AEIs occurring within 7 days postvaccination, 
using passive surveillance of general practitioner (GP) 
EHR systems enhanced by a card-based ADR reporting 
system. Extracted data will be presented overall by brand 
(Fluarix Tetra vs others), by age strata and risk groups. The 
secondary outcome measure is the vaccine uptake among 
the subjects registered in the enrolled general practices.
Ethics and dissemination Ethical approval was granted 
by the Proportionate Review Sub-committee of the North 
East—Newcastle & North Tyneside 2 on 5 August 2016. 
The study received approval from the Health Research 
Authority on 1 September 2016. We will produce an 
interim analysis within 8 weeks, and an end-of-study 
report, which will be submitted to peer-reviewed journals.
INTRODUCTION
EMA guidance
In response to a recent expansion of national 
vaccination programmes in European Union 
(EU) member states, the European Medi-
cines Agency (EMA) has released interim 
guidance on enhanced safety surveillance for 
seasonal influenza vaccines in the EU.1 This 
set out new standards for surveillance that 
all marketing authorisation holders (MAHs) 
providing vaccines in the EU must address. 
The key objective of the EMA enhanced safety 
surveillance is to rapidly detect a significant 
increase in the frequency and/or severity of 
expected reactions (local, systemic or allergic 
reactions) that may indicate a potential or 
more serious risk as exposure to the vaccine 
increases.
Since 2015, European regulatory 
requirements to evaluate the safety and immu-
nogenicity of seasonal influenza vaccines in 
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Protocol
Strengths and limitations of this study
 ► This study sets out the first methods for near-real-
time enhanced passive surveillance of seasonal 
influenza vaccine using routinely collected data.
 ► Customised adverse drug reaction cards may 
enhance reporting over standard passive 
surveillance, which may result in under-reporting 
of less severe symptoms not requiring medical 
attendance.
 ► The methods outlined in this study have the potential 
to be expanded to other brands.
 ► The practice recruitment is intended to have wide 
and representative coverage of England.
 ► The data of the participating patients will be 
thoroughly protected by means of a pseudonymising 
algorithm that allowed removal of strong identifiers.
 ► This feasibility study has not been powered or 
designed to detect rare events or detect significant 
statistical differences of adverse event rates across 
brands.
 ► We are also exploring the feasibility of using rates 
of adverse events in non-vaccinated patients as a 
basis for comparison.
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small-scale clinical trials were withdrawn.2 Such trials had 
insufficient power to adequately evaluate safety concerns 
arising from annual formulation changes (eg, adverse 
events occurring at a rate of 1%–2%). These clinical trials 
are to be replaced by enhanced, preferably active, safety 
monitoring and vaccine effectiveness assessments.
The EMA Interim Guidance on enhanced safety 
surveillance for seasonal influenza vaccines in the EU 
suggested that there would be three options envisioned 
for enhanced surveillance:
 ► Enhanced active surveillance (post-authorisation safety 
studies): active follow-up of a cohort of children 
and adults for 7 days after immunisation for 
reactogenicity end points/adverse events.
 ► Enhanced passive surveillance: rapidly estimate vaccine 
usage and facilitate adverse drug reaction (ADR) 
reporting in order to determine reporting rate as 
a surrogate of incidence of the adverse events of 
interest (AEI).
 ► Data mining or other use of electronic health 
record (EHR)/ computerised medical 
record (CMR).
We opted for enhanced passive surveillance 
because while highly computerised medical record 
systems maximise the likelihood of reliably capturing the 
AEIs, we felt this needed enhancement through the use of 
customised ADR cards. These cards were preprinted with 
the categories of possible adverse events to facilitate the 
reporting and the subsequent coding of events. They also 
contained a specific tick box when no AEIs were experi-
enced leading to a reasonably acceptable return rate.
We expect that by enhancing surveillance with a custom-
ised card and encouraging patients to directly report their 
symptoms, we will more reliably detect a greater number 
of events. The proposed approach was designed to meet 
the EMA enhanced passive surveillance definition.
The present collaborative pilot study between marketing 
authorisation holder GlaxoSmithKline Biologicals (GSK) 
and the Clinical Informatics and Health Outcomes 
Research Group at the University of Surrey builds on the 
lessons learnt from the pilot study (EPI-FLU-045 VS UK) 
implemented during the 2014/2015 influenza season 
and aims to address the EMA commitment for enhanced 
safety surveillance of seasonal vaccines in Europe. We will 
begin data collection on 1 September 2016, and the anal-
ysis will be completed on 31 March 2017.
The EPI-FLU-045 VS UK pilot study showed that the 
proposed surveillance setting in the UK was suitable to 
rapidly detect and evaluate potential new safety concerns 
each influenza season. The primary purpose of the 
2016/2017 pilot study is to improve the combination of 
an ADR card-based system and the use of routine data to 
collect adverse events following vaccination with seasonal 
influenza vaccines.
The RCGP RSC network
The Clinical Informatics Research Group, in the Depart-
ment of Clinical and Experimental Medicine at the 
University of Surrey, is the home of the data and anal-
ysis hub for the Royal College of General Practitioners 
Research and Surveillance Centre (RCGP RSC). The 
RCGP RSC provides a national primary care surveil-
lance system and is supported by Public Health England 
(PHE). The RCGP RSC network of practices has a 
membership designed to give representative coverage 
of 1.5%–2% of the English population.3 The RCGP 
RSC has been described as the gold standard sentinel 
network.
The most important work of the RCGP RSC network 
is its influenza surveillance; many practices have been 
involved in this work for decades.4 Data are uploaded 
from the network on a weekly basis to a secure sever, with 
the possibility to switch the frequency of the release to 
a twice-weekly upload during epidemics. The methods 
developed by the University of Surrey will be used in this 
passive enhanced safety surveillance study, with a focus on 
reporting on adverse events.
Seasonal influenza vaccination in England
Seasonal influenza vaccines present several specific 
challenges for pharmacovigilance. These include immuni-
sation in large population cohorts in a relatively short and 
fixed time period each year, and multiplicity of vaccine 
products on the market with the need to conduct prod-
uct-specific safety surveillance. In the UK, the 2015/2016 
influenza plan recommended the following groups to be 
vaccinated5 :
 ► People aged 65 years or over (based on age on 31 
March 2016);
 ► People aged from 6 months to less than 65 years 
with a medical condition: chronic (long-term) 
respiratory disease, such as severe asthma; chronic 
obstructive pulmonary disease or bronchitis; chronic 
heart disease, such as heart failure; chronic kidney 
disease, stages 3–5; chronic liver disease; chronic 
neurological disease, such as Parkinson’s disease 
or motor neuron disease, or a learning disability; 
diabetes; splenic dysfunction; immunocompromised 
due to disease (such as HIV/AIDS) or treatment 
(such as cancer treatment);
 ► All pregnant women (including those women who 
become pregnant during the influenza season);
 ► All those aged 2, 3 and 4 years (but not 5 years or 
older) on 31 August 2015 (ie, date all children 
of school years 1 and 2 age through locally 
commissioned arrangements);
 ► Primary school-aged children in areas that 
participated in primary school pilots in 2014/2015;
 ► People living in long-stay residential care homes or 
other long-stay care facilities;
 ► People who are in receipt of a carer’s allowance, or 
those who are the main carer of an older or disabled 
person;
 ► Household contacts of immunocompromised 
individuals.
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The list above is not exhaustive, and the healthcare practi-
tioner should apply clinical judgement to take into account 
the risk of influenza exacerbating any underlying disease.
Expansion of national vaccination has created a 
greater need for timely information and reassurance on 
the balance of risks and benefits for those receiving the 
vaccines. The collaborative pilot study is conceived in 
response to the EU requirements triggered by the EMA’s 
call for enhanced safety surveillance in Europe. The 
continuation of the pilot study in the 2016/2017 season 
will help to build a framework for passive enhanced safety 
surveillance in England, but will also contribute to an 
EU-wide programme of enhanced safety surveillance for 
seasonal influenza vaccines.
RESEARCH METHODS
This published protocol is a summary of the full protocol, 
submitted for ethical approval, and the long version is 
available as an online supplementary material.
Objectives and end points
Primary objective
To estimate on a weekly basis the crude and cumulative 
incidence rate of AEIs within 7 days following vaccination 
with a seasonal influenza vaccine, using passive surveil-
lance of general practitioner (GP) EHR systems enhanced 
by a card-based ADR reporting system. Extracted data will 
be presented overall, by brand (Fluarix Tetra vs others), 
by EMA defined age strata and UK Department of Health 
Chief Medical Officer (CMO)- specified risk groups.
Secondary objective
To estimate on a weekly basis the vaccine uptake among 
the subjects registered in the enrolled GP practices, by age 
strata (6 months to 5 years; 6–12 years; 13–18 years; ≥18–65 
years; >65 years) and CMO-specified risk groups.
Primary end points
Occurrence and onset dates of AEIs within 7 days post-
vaccination reported using a card-based ADR reporting 
system in vaccinated patients overall, by brand (also indi-
cating those for whom brand data are unavailable), by 
age strata (6 months to 5 years; 6–12 years; 13–17 years; 
18–65 years; >65 years) and CMO-specified risk groups. 
AEIs will be presented by categories depending of the 
nature of the event.
 ► Fever or other febrile illness
 ► Local reactions
 ► General reaction (eg, fatigue and myalgia)
Secondary end points
Seasonal influenza vaccination status among the subjects 
registered in the enrolled GP practices, vaccine brand, 
by age strata (6 months to 5 years; 6–12 years; 13–18 
years; ≥18–65 years; >65 years) and CMO-specified risk 
groups and date of vaccine administration collected in the 
CMR system.
Study design
Study setting and population
The proposed pilot study (EPI-FLU-046 VS UK) is to 
follow a cohort of patients who would be exposed to 
seasonal influenza vaccination in the months between 
1 September 2016 and 30 November 2016. The final data 
collection will occur on 10 January 2017 to allow for any 
delays in records of up to 6 weeks.
Invitation letters will be sent to GP practices ordering 
mainly GSK’s Fluarix Tetra vaccine for the 2016/2017 
season, and evenly representative of geographical loca-
tions and systems. Practices will be reimbursed for their 
involvement in this study, according to the National 
Institute of Health Research guidelines for industry-spon-
sored studies.6
For this pilot project, routinely collected primary care 
data from up to 10 GP practices will be extracted, to 
provide passive surveillance. However, this passive surveil-
lance is enhanced by all practices additionally using a 
card-based ADR reporting system. In last year’s study, the 
card-based ADR reporting system used the Yellow Card 
developed by the UK Medicines and Healthcare products 
Regulation Agency. We have developed a more specific 
ADR card for use in this study, which will be distributed to 
practices. The new ADR card is preprinted with the cate-
gories of likely AEIs the EMA require surveillance for, to 
facilitate the recording of AEIs and to make their coding 
into the GP EHR system easier. There was also a tick box 
for no AEI.
Patients will be provided with the appropriate ADR 
reporting card and invited to return the card to the GP 
practices within 7 days, but not later than 14 days, postvac-
cination.7 To protect confidentiality, this ADR card will be 
returned to the practice, and data from it will be recorded 
in that patient’s EHR. The data will be used to estimate 
proportions of AEIs among influenza-vaccinated individ-
uals.
Inclusion criteria
All patients receiving a seasonal influenza vaccine between 
1 September 2016 and 30 November 2016 in 1 of the 10 
volunteer practices are eligible for inclusion in the anal-
ysis. The main inclusion criteria for practices is that they 
state their principal vaccine supplier will be GSK.
Exclusion criteria
Patients who have explicitly opted out of data sharing 
will be excluded from the analysis. We will identify these 
patients using the opt-out codes within GP information 
systems where the patients have made an explicit choice 
to opt out; patients will be informed of their option to 
opt out via posters in the practices and information sheets 
accompanying the ADR cards.
Sample size calculation
The average practice size in England and Wales is 
7034,8 and we estimate that data will be collected on a 
population of approximately 70 340 patients (across 10 
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practices). In the period from September to December 
2015, the seasonal influenza vaccine uptake for 
those over 65 years old was 71.0%; for those in a clinical 
risk group aged 6 months to 65 years, the uptake was 
45.1%; and for pregnant women, it was 42.3%. We have 
estimated influenza vaccine uptake using the coverage 
estimates published by PHE.9
The minimum needed target population to be medi-
cally followed by the GPs is estimated at 50 000 subjects 
(approximately 5000 per practice). We expect to enrol 
at least 5000 vaccinated subjects with 7 days of follow-up 
after vaccination (as per EMA interim guidance request). 
This sample size estimation sets out to estimate the prob-
ability to observe at least one AEI in the study population 
and evaluate the level of ‘certainty’ around this finding; 
this is over the 14-week period of enhanced surveillance 
(1 September to 30 November 2016).
We have not taken into account any effect of clustering 
in our surveillance study design or power calculation. 
Similarities, or homogeneity, between subjects in clusters 
reduce the variability of their responses, compared with 
that expected from a random sample.
The cluster effect has not been taken into consid-
eration in the calculation of the sample size. It may 
increase the relative SE (RSE) and thus decrease the 
precision around the proportions presented below. 
Nevertheless, this will be accounted for during the anal-
ysis.
Table 1 shows the 95% CI, the probability of 
observing at least one AEI during the study period in 
the study cohort and the RSE for a range of scenarios 
in terms of cohort size, vaccine coverage and expected 
probability of AEI.10 With an overall sample size of a 
minimum of about 50 000 subjects medically followed 
by the enrolled GP practices, a follow-up period of 
14 weeks, a vaccine coverage of 5%, 10% or 20% and 
an expected probability of AEI varying from 0.01% 
to 20%, the corresponding probability to observe at 
least one event in our study population varies from 
2% to 100%, and the associated RSE varies from 2.0% 
to 200% depending on the scenario.
Table 2 shows the evolution by week of the 95% CI, the 
cumulative probability of observing at least one AEI in 
the study cohort and the RSE in the course of the study 
for a range of scenarios in term of cohort size, vaccine 
coverage and probability of AEI of 1%. With an overall 
sample size of a minimum of about 50 000 subjects medi-
cally followed by the enrolled GP practices, a follow-up 
period of 14 weeks and a vaccine coverage of 5%, 10% 
or 20%, the corresponding probability to observe at least 
one event in our study population varies from 53% to 
99% after week 1, and the associated relative SE varies 
from 53% to 37% depending on the scenario.
Data sources
In this passive enhanced safety surveillance, there are 
two data sources: general practice EHR data, providing 
passive surveillance, and ADR cards completed by 
patients providing the enhanced component. The ADR 
cards are being returned to the patient’s own practice 
to ensure confidentiality. The data from these cards 
would also be coded into the EHR and uploaded weekly 
(figure 1).
1. General Practice EHR data recorded by the practice 
team. Weekly data about vaccine exposure and any 
subsequent AEIs will be uploaded (anonymised) 
to the University of Surrey. The EHR data contains 
both AEIs recorded by the practice team as well 
as data reported to the practice on an ADR by a 
vaccinated patient.
2. ADR cards completed by patients. Among the 10 
participating GP practices, patients who are 
vaccinated against influenza will be provided ADR 
cards. These ADR cards, customised following 
practice feedback to match EMA requirements, 
collect AEIs reported after the receipt of influenza 
vaccination.
These data originating from the two sources (patient 
completed ADR card or practice recorded) will be then 
imported (anonymised) into the secure servers of the 
University of Surrey. The final dataset will therefore 
combine data routinely collected for all patients regis-
tered with the 10 participating sites and data collected 
form the ADR cards and encoded during the 2016/2017 
influenza season. In addition to the adverse event data, 
we will extract demographics, vaccination status and rele-
vant comorbidities.
We will only extract coded data, that is, where the GP 
or other health professional codes a disease or symptom 
into the EHR system.11 The overwhelming majority of 
the large volume of research that has come out of UK 
primary care is based on coded data.12 The richness of 
primary care data are such that we anticipate being able 
to detect important AEIs.13 We will request practices to 
use the relevant Read code for ADR notifications, when 
recording data from a returned card (Read Code: 9G4 
Adverse drug reaction notification).
Data analyses
We will interpret coded data by the creation of ontolo-
gies that we will map to case definitions, where available. 
However, we do not have the in-depth descriptions 
required for case definition found, for example, in 
clinical trials. We will be inferring meaning from brief 
clinical coded information, though we have consider-
able experience of this and will have the opportunity to 
confirm with practices and practitioners how to inter-
pret their clinical records.
Statistical analysis will consist primarily of descrip-
tive statistics: rates and proportions for categorical 
data and summary statistics for continuous variables. 
Confidence intervals will be calculated; however, due 
to the effects of clustering and practice differences 
in this relatively small pilot, these are likely to be 
wide. All statistical analyses will be conducted using 
R Studio.
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Analyses of the primary objective
All analyses will be carried out by overall, by brand 
(Fluarix Tetra vs others), by age strata (6 months to 5 
years; 6–12 years; 13–17 years; 18–65 years; >65 years) 
and CMO-specified risk groups.
To estimate on a weekly basis the crude incidence rate 
of AEIs within 7 days,
 ► the denominator will consist of the number 
vaccinated subjects receiving a vaccination card and 
reaching 7 days of follow-up postvaccination during 
the week of interest and cumulatively since the 
beginning of the study.
 ► The numerator will encompass all vaccinated subjects 
reporting at least one AEI within 7 days following 
vaccination with a seasonal influenza vaccine.
ETHICS AND DISSEMINATION
Ethical review
In ‘Defining Research’ (http://www. hra. nhs. uk/ docu-
ments/ 2013/ 09/ defining- research. pdf), the National 
Research Ethics Service (NRES) guidance suggests that 
surveillance does not require formal review by a Research 
Ethics Committee. The research team will however seek 
an opinion from the NRES’s Proportional Review system 
to check if formal approval from a NHS Research Ethics 
Committee (REC) is needed prior to the commence-
ment of the study, as well as Section 251 approval. Ethical 
approval was granted by the Proportionate Review 
Sub-committee of the North East—Newcastle & North 
Tyneside 2 REC on 5 August 2016 (REC reference: 16/
NE/0271). Section 251 application was not deemed 
necessary by the Health Research Authority and the 
study received approval on 1 September 2016 (IRAS ID: 
2 11 560).
Data extraction and data management
The method and governance procedure has been devel-
oped by the University of Surrey, using an approved 
provider, Apollo Medical Software Solutions. Alternatively, 
we will use another approved data extraction supplier or 
securely extract the relevant study data ourselves using 
standard data extraction tools such as Morbidity Informa-
tion Query Export Syntax (MIQUEST), a Department of 
Health sponsored data extract tool. Data extractions will 
be conducted in accordance with the Research Group’s 
standard operating procedures in data extraction, pseud-
onymisation and transfer.
All data are strongly encrypted by a combination of 
symmetric and asymmetric encryption algorithms, Triple 
DES1 and RSA 10242 before transmission, and utilises 
public and private key pairs unique to each project. Data 
are pseudonymised as near to source as possible. Pseud-
onymisation is applied at this stage to allow for backwards 
identification should there be a need to do so as part of 
an ethically approved study.
Pseudonymisation is a process that involves the removal 
of all personal identifiers from data—such as name, date 
of birth and so on. However, there is a risk that if data 
are linked to other data, a person might be identified.14 
Therefore, although all identifiers are removed, we keep 
data encrypted during transfer and on a secure network 
that meets NHS Information Governance standards to 
minimise the risk of reidentification. Pseudonymisation 
is the standard approach for this type of surveillance. A 
legally binding definition of pseudonymisation has been 
Figure 1 Data capture flowchart : patient receiving 
influenza vaccination in the surgery.
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introduced into European law15 on the recommendation 
of the European Data Protection Supervisor.16
All data processing and analysis in the present proposed 
study will be conducted within the secure IT environment 
of the Clinical Informatics Research Group, at the Univer-
sity of Surrey. The information security policies and 
procedures of the Research Group have been approved 
by the NHS Health and Social Care Information Centre 
as meeting Information Governance Toolkit standards.17 
The University of Surrey is registered with the Informa-
tion Commissioner’s Office Data Protection Register and 
is compliant with the Data Protection Act and other legis-
lations.
In line with the principle of the Data Protection Act 
1998, data subjects will be informed of the uses of their 
data in this study. Participating GP practices will be asked 
to display project information in their website, and project 
information posters in reception areas, from when the 
practice has consented to take part in the study and until 
the study is completed. We will respect the codes in the 
data indicating that a patient does not wish to have their 
record available for research; we will, however, seek to 
report the number of patients within a practice who have 
chosen to opt out.
No personally identifiable information, such as NHS 
numbers, postcodes, dates of birth and so on, will be avail-
able to GSK, third parties or disclosed in publications. 
Additionally, no patient-level data will be sent to GSK to 
remove any possibility that any individual patient might 
be reidentified. GSK will also be blinded to practice iden-
tities and the locality at which any AEI occurs, other than 
where the patient gives consent or on their own chooses 
to report any condition in line with best practice.
Safety reporting, including routine pharmacovigilance
This study’s primary end points are safety related. 
However, it will be clearly communicated to participating 
practices that the study does not replace AEI reporting 
that would occur as part of routine practice. If a GP felt an 
AEI merited reporting, they should do so in whatever way 
they would generally do so. If the team at the University 
of Surrey becomes aware of a serious adverse event (SAE) 
experienced by a study participant, the SAE should be 
reported to GSK within 24 hours of awareness, in writing. 
An SAE is defined as any untoward medical occurrence 
that
 ► Results in death,
 ► Life-threatening (where the participant is at risk of 
death),
 ► Requires hospitalisation or prolongation of existing 
hospitalisation,
 ► Results in disability/incapacity (where there is a 
substantial disruption of a person’s ability to conduct 
normal life functions),
 ► Important medical events: events that may not be 
immediately life threatening or result in death 
or hospitalisation but may jeopardise the study 
participant or may require medical or surgical 
intervention to prevent one of the other outcomes 
listed in the above definition.
Dissemination and public register disclosure
The outputs from the research will be disseminated 
primarily through peer-reviewed papers in high-impact 
journals within the domains of primary care, surveillance, 
vaccines and infectious diseases.18 19 We will present 
findings at relevant seminars and conferences. The 
University of Surrey, in accordance with GSK policy, will 
post a summary of the study protocol and results within 
12 months of study completion and following review and 
comment by GSK on GSK’s Clinical Study Register (acces-
sible at http://www. gsk- clinicalstudyregister. com and at 
www. clinicaltrials. gov).
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